B+
Bull case
20%
Probability
Target price
$65.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
NKTR
Nektar TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
If pivotal studies reproduce durable benefit and acceptable safety, rezpegaldesleukin could gain value across two dermatology indications. Nektar reported $1.02 billion of cash and investments at June 30, 2026 and projected runway into the third quarter of 2028, beyond its expected initial Phase 3 readouts.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +12.6.
What can break
Pivotal-trial efficacy, safety, enrollment, manufacturing and regulatory timing remain uncertain; Fast Track designation does not assure approval. [#8-K-2026-10-01]
Momentum
2
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $65.00 · Bear $17.00Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $133.08
Why
Momentum2 · Δ7d +0.0
Value41 · Δ7d -0.1
Sentiment54 · Δ7d +12.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +12.6.
Contradictions & invalidation
- • Pivotal-trial efficacy, safety, enrollment, manufacturing and regulatory timing remain uncertain; Fast Track designation does not assure approval. [#8-K-2026-10-01]
- • Post-print analyst revisions and a verified close-to-close October 1 price move are unavailable in the packet; the reported selloff should not be treated as a measured return.
- • The October alopecia durability result involved only eight evaluable patients at six months off treatment, leaving substantial replication risk.
Catalyst clock
2027-03-31
ZENITH AA Phase 3 initiation
Lead driver: Sentiment · See AI snapshot
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-1.7
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
54
45% active weight
Current posture
7d trendImproving
Δ7d
+12.6
Δ21d
-46.7
Why this grade
Composite grade D. Momentum 1.9 / Value 40.6 / Sentiment 53.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$1.28B
Beta
1.35
Shares Out
34.14M
P/E (TTM) · Derived
-3.9
P/S (TTM)
14.45
P/FCF (TTM) · Derived
-3.80
Rev YoY
-9.3%
EPS YoY
-58.4%
Gross Margin
+98.7%
Op Margin
-239.3%
Net Debt
-$96.84M
Current Ratio
10.42
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data